For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM) and…
Blog
Trump’s State of the Union: A closer look at the claims
Last night, President Trump delivered a State of the Union address filled with optimism, applause lines, and bold claims about the country’s direction. There…
Search Posts
Letters
CEI Joins Coalition Letter on Fixed Drug Pricing
Dear Republican Members of the House and Senate, We represent fiscal conservatives and free market activists from across the country, and we are concerned about…
Inside Sources
Federal Children’s Environmental Health Grants Used to Peddle Junk Science
For more than two decades, the federal government has doled out millions of dollars to fund university-based “children’s environmental health centers.” These centers operate under…
Fox News
Pelosi, Progressive Caucus Clash over Drug Pricing Legislation
Fox News cites Research Fellow Patrick Hedger on Nancy Pelosi’s proposed “Lower Drug Costs Now Act.” But according to the right-leaning Competitive Enterprise…
Townhall
The Black Market Is the Real Problem with Vaping
Townhall cites Senior Fellow Michelle Minton on e-cigarettes and the black market. But, as Michelle Minton of the Competitive Enterprise Institute stated after…
News Release
House Bill Setting Price Controls on Medicines Would Endanger Patients, Harm Innovation
House Speaker Nancy Pelosi and Majority Leader Steny Hoyer plan to bring H.R. 3, the Lower Drug Costs Now Act, to the floor for a…
Real Clear Markets
With Drug Pricing, Bipartisanship Isn’t an Excuse to Violate the Laws of Economics
In an age of intense political polarization, some may assume anything that House Speaker Nancy Pelosi and President Donald Trump even marginally agree on has…